Abridged Review of a Generic Chewable Tablet: What to Query and What to Refuse
Ms Amina is a regulatory affairs officer at a Nairobi manufacturer. She submits an application to register Aldazil Plus 400, a chewable albendazole 400 mg tablet, as a generic of a well-established reference product. The dossier has four problem areas. First, the bioequivalence study - 24 subjects at a single foreign site the PPB has never inspected - with no GCP oversight documentation. Second, six months of accelerated stability data at 40°C/75% RH and no long-term data. Third, a GMP certificate for the foreign manufacturing site issued by an authority that is not on the PPB's list of recognised authorities. Fourth, the product is already registered in two other countries. The proposed brand name uses 'Plus' although there is no additional active ingredient, and the package insert claims 'faster relief than other brands'. The evaluator has 30 working days to respond and is considering an abridged review.
1. Classify each deficiency as curable by query or fatal to the application, and state your decision for the 30-day response.
Read the worked answer
Decision: issue a deficiency letter (query), not an outright refusal - but make clear that approval cannot proceed on the current data. None of the four gaps is by itself a statutory bar, yet each attacks a different pillar of an abridged review.
- Bioequivalence. In an abridged review the BE study is the pivotal evidence. A never-inspected site is not automatically disqualifying, but you cannot verify GCP or data integrity from a certificate alone. Request the full protocol, ethics approval, GCP compliance statement, site details and raw data; then either accept documented GCP oversight by a recognised authority or arrange a site inspection. If the study cannot be verified, the application fails on its pivotal evidence.
- Stability. Six months accelerated only cannot support a shelf life. Require 12 months long-term data at 30°C/75% RH (Kenya sits in Zone IVb) plus an ongoing stability commitment.
- GMP. A certificate from a non-recognised authority is weak evidence. Require a PPB inspection, or an inspection report from a recognised authority covering the actual line and dosage form.
- Prior registrations support but do not substitute for Kenyan requirements.
Set a firm response deadline rather than letting the 30 days lapse in silence; record each deficiency and its resolution in the evaluation report.
2. How do you deal with the 'Plus' suffix and the comparative efficacy claim?
Read the worked answer
Both are labelling and promotion problems, not data problems - and neither is negotiable.
- 'Plus' with a single active ingredient implies an additional ingredient or enhanced effect that does not exist. It is misleading, and it creates a real look-alike risk because 'Plus' products in the same therapeutic class often do contain a second active. Pharmacovigilance and dispensing errors follow brand names that misdescribe composition.
- 'Faster relief than other brands' is a comparative promotional claim. For a generic it is unsubstantiated; even if substantiated, promotion must be consistent with the approved SPC and cannot exceed the reference product's indications.
Advise resubmission as 'Albendazole 400 mg chewable tablets - [Brand]', deletion of the comparative claim, and an insert aligned with the reference SPC. A sticker over printed packaging is not an acceptable fix; that is the applicant's commercial risk, not a reason to approve. Record the labelling decision explicitly in the evaluation report so that post-approval advertising cannot quietly resurrect the claim.
3. What GMP and bioequivalence evidence would you actually accept, and on what principle?
Read the worked answer
Apply a risk-based reliance principle: reliance is a formal, recorded regulatory decision, not an informal waiver.
GMP. Accept a certificate plus the recent inspection report from a recognised authority with a positive outcome for the same dosage form, a site master file, and evidence that critical and major findings are closed. If no recognised authority has inspected the site, the options are a PPB inspection, acceptance under a mutual recognition or reliance arrangement, or an inspection by a designated third party. A certificate alone, with no report and no scope, proves little.
BE. Accept data from a site with documented GCP oversight: ethics approval, monitoring evidence, a GCP compliance statement, and raw data on request. Check the design itself - fasting or fed as appropriate, adequate washout, 90% CI within 80–125% for AUC and Cmax, and a reference product sourced from a market with adequate oversight.
If neither route can be satisfied, advise that the study may need repeating at an acceptable site. Document which authority you relied on and why, so the decision is defensible on review.